CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-12 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −2,568 | $23.53 | $60K | 125,066 |
| 2025-02-12 | Inrig Jula CHIEF MEDICAL OFFICER | Sale | −2,568 | $23.53 | $60K | 89,602 |
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +10,000 | $16.23 | $162K | 73,654 |
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −10,000 | $25.00 | $250K | 63,654 |
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +10,000 | $17.44 | $174K | 73,654 |
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −10,000 | $25.00 | $250K | 63,654 |
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +10,000 | $17.96 | $180K | 73,654 |
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −10,000 | $25.00 | $250K | 63,654 |
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +15,000 | $15.46 | $232K | 78,654 |
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −15,000 | $25.00 | $375K | 63,654 |
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −9,244 | $25.00 | $231K | 54,410 |
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2025-02-11 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Employee stock option (right to buy) 10b5-1 | −15,000 | 0 | ||
| 2025-02-11 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −3,074 | $25.00 | $77K | 127,634 |
| 2025-02-11 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −11,375 | $24.04 | $273K | 419,173 |
| 2025-02-10 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Option exercise 10b5-1 | +8,000 | 103,719 | ||
| 2025-02-10 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Option exercise · Performance-based restricted stock units 10b5-1 | −8,000 | 0 | ||
| 2025-02-10 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Option exercise 10b5-1 | +8,000 | 97,482 |
Page 19 of 51 · 1,020 trades